Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Unknown 3Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 27Head & Neck 3Gastrointestinal 3Dermatologic 3Tumor-Agnostic 2Thoracic 2Genitourinary 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1CNS 1

Conditions

Melanoma 3Neoplasm Metastasis 1

Interventions

Nivolumab 27pembrolizumab 22Ipilimumab 17Temozolomide 13toripalimab 12Biopsy 10Cyclophosphamide 9Imiquimod 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5fludarabine 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Interleukin-2 4Injections 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × palbociclib × Dermatologic × Clear all
NCT04720768 2024-01-05

CELEBRATE

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Unknown
78 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT03454919 2018-03-06

Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations

Peking University Cancer Hospital & Institute

Phase 2 Unknown
60 enrolled
Dermatologic

Melanoma

NCT02202200 2016-04-18

OPTIMUM

Assistance Publique - Hôpitaux de Paris

Phase 1/2 Unknown
40 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡